Optimizing Care of Patients with Rheumatoid Arthritis: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based Care
CMEO Live and On DemandPremiere Date: Wednesday, August 10, 2011
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date: Friday, August 10, 2012
Leonard H. Calabrese, DO (Moderator)
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
R. J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic Foundation
Allan Gibofsky, MD, JD, FACP, FCLM
Professor of Medicine and Public Health
Weill Medical College of Cornell University
Hospital for Special Surgery
New York, NY
William F. C. Rigby, MD
Vice Chairman of Academic Affairs
Professor of Medicine
Department of Medicine
Dartmouth Medical School
New and emerging strategies for diagnosing rheumatoid arthritis (RA) are continually being explored in research, and many show promising and effective application for real-world clinical practice. To facilitate diagnosis and therefore early treatment of the disease, clinicians should be aware of validated assessment tools, which can be effectively applied in real-world practice settings. Further, monitoring of disease activity and progression using an outcome measure is a valuable and important practice in the optimization of treatment for patients with RA. Current guidelines advocate for the early and sustained use of DMARD therapy in RA. However, clinicians require a more thorough understanding of different strategies in selecting appropriate combination DMARD therapy for each patient, which will ultimately increase chances of remission.(1)
In this CME Outfitters Live and On Demand activity, expert faculty will comprehensively analyze and discuss strategies for early diagnosis, early and sustained DMARD therapy, and measurement-based care that will help clinicians improve care of their patients with RA.
- Dale J, Alcorn N, Capell H, Madhok R. Combination Therapy for Rheumatoid Arthritis: Methotrexate and Sulfasalazine Together or With Other DMARDs. Nat Clin Pract Rheumatol CME 2007;3:450-458. http://www.medscape.org/viewarticle/560135 Accessed March 11, 2011.
Use of diagnostic strategies and measurement-based care tools and principles to optimize management and improve quality of life for patients with rheumatoid arthritis.
At the end of this CE activity, participants should be able to:
- Apply new diagnostic strategies for rheumatoid arthritis to facilitate early diagnosis of the disease.
- Utilize validated outcome measures to monitor disease activity and progression and ultimately optimize therapy for individual patients with RA.
- Integrate guidelines and strategies for combination DMARD therapy to facilitate more appropriate DMARD selections for patient therapy.
The following learning objectives pertain only to those requesting CNE credit:
- Identify the purpose and uses of new diagnostic strategies for rheumatoid arthritis.
- Name disease outcome measures used to monitor disease activity and progression in patients with rheumatoid arthritis.
- Recognize guidelines and distinguish among currently available strategies for combination DMARD therapy.
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals with an interest in rheumatoid arthritis.
Supported by educational grants from Pfizer Inc. and Abbott Laboratories.
Additional support has been provided by CME Outfitters, LLC.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Activity Number: 0376-9999-11-009-H01-P (recorded programs)
Activity Type: knowledge-based
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Calabrese has disclosed that he serves on the speakers bureau of Amgen Inc.; Bristol-Myers Squibb; Centocor Ortho Biotech Inc.; Genentech, Inc.; and Hoffmann-La Roche Inc. He serves as a consultant to Bristol-Myers Squibb; Centocor Ortho Biotech Inc.; Genentech, Inc.; Pfizer Inc.; and Hoffmann-La Roche Inc.
Dr. Gibofsky has disclosed that he serves on the speakers bureaus of Abbott Laboratories; Amgen Inc.; Pfizer Inc.; Hoffmann-La Roche Inc.; and UCB, Inc. He serves as a consultant to Abbott Laboratories; Amgen Inc.; Pfizer Inc.; Hoffmann-La Roche Inc.; and UCB, Inc. He is a stock shareholder of Abbott Laboratories; Amgen Inc.; Bristol-Myers Squibb; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; and Pfizer Inc.
Dr. Rigby has disclosed that he receives grants/research support from, and serves on the speakers bureau of Hoffmann-La Roche Inc. He serves as a consultant to Hoffmann-La Roche Inc. and UCB, Inc.
Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.
Ruth Cody, BSN, RN-BC (Content/Peer Reviewer) has no disclosures to report.
Tony Graham, MD (Content/Peer Reviewer) has no disclosures to report.
Nancy Jennings, MSN, MBA, MHA, RNC (Content/Peer Reviewer) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Christina Ansted, MPH (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
USF Health, CME Outfitters, LLC, the faculty, Abbott Laboratories, and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
This document was last modified on: